Idexx Laboratories (IDXX) insider trading

By person

29 insiders · 739 transactions

51.1×

Jonathan J. Mazelsky holds 51.1 times base salary in stock. $58.80M of shares against $1.15M in salary for 2025.

Salary from the company's own proxy. The shares are what Jonathan J. Mazelsky last reported holding, valued at $701.69, the price Common Stock was last bought or sold at on the open market here, on 4 Nov 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Jonathan W Ayers

Director

—

$311.03M (245) scheduled

−$311.03M

158,256

0.2009%

$111.05M

−70.1%

Brian P McKeon

EVP, CFO and Treasurer

—

$100.51M (66) scheduled

−$100.51M

49,600

0.0630%

$34.80M

+44.8%

Jonathan Jay Mazelsky

Executive Chair of the Board

—

$97.28M (92) scheduled

−$97.28M

83,803

0.1064%

$58.80M

+520.6%

Giovani Twigge

Senior Vice President

—

$43.99M (29) scheduled

−$43.99M

20,329

0.0258%

$14.26M

+10.5%

James F Polewaczyk

Executive Vice President

—

$35.68M (25) scheduled

−$35.68M

10,711

0.0136%

$7.52M

−28.7%

Michael Lane

Executive Vice President

—

$29.55M (36) scheduled

−$29.55M

4,668

0.0059%

$3.28M

+10.2%

M Anne Szostak

Director

—

$20.42M (32) scheduled

−$20.42M

778

0.0010%

$545.91K

−94.6%

Nimrata Hunt

Executive Vice President

—

$17.23M (14) scheduled

−$17.23M

18,141

0.0230%

$12.73M

+74.1%

George Fennell

Executive Vice President

—

$16.66M (14) scheduled

−$16.66M

10,433

0.0132%

$7.32M

+104.6%

Kathy Turner V

Senior Vice President

—

$16.12M (24) scheduled

−$16.12M

7,380

0.0094%

$5.18M

+135.3%

Rebecca M Henderson

Director

—

$13.87M (14) scheduled

−$13.87M

14,696

0.0187%

$10.31M

−31.5%

Daniel M Junius

Director

—

$12.22M (13) scheduled

−$12.22M

2,361

0.0030%

$1.66M

—

Sophie Vandebroek V.

Director

—

$10.49M (13) scheduled

−$10.49M

9,078

0.0115%

$6.37M

+51.3%

Sharon E. Underberg

EVP, GC & Corporate Secretary

—

$9.68M (4) scheduled

−$9.68M

7,169

0.0091%

$5.03M

+1,866%

Jacqueline Studer

CVP, Gen. Counsel & Secretary

—

$8.64M (16) scheduled

−$8.64M

4,389

0.0056%

$3.08M

+77.0%

Bruce L. Claflin

Director

$280.06K (2)

$6.63M (5) scheduled

−$6.35M

1,721

0.0022%

$1.21M

—

William T End

Director

—

$4.78M (5)

−$4.78M

31,786

0.0403%

$22.30M

−40.8%

Michael G Erickson

Executive Vice President

—

$3.63M (8) scheduled

−$3.63M

15,092

0.0192%

$10.59M

+59.4%

Thomas Craig

Director

—

$1.02M (1) scheduled

−$1.02M

24,471

0.0311%

$17.17M

+7.1%

Lawrence D Kingsley

Director

$1.23M (5)

$1.17M (1) scheduled

+$57.64K

9,568

0.0121%

$6.71M

—

Andrew Emerson

EVP, CFO and Treasurer

—

4,421

0.0056%

$3.10M

+79.6%

Michael Schreck

Executive Vice President

—

3,089

0.0039%

$2.17M

+397.6%

Michael Perkins Johnson

Executive Vice President

—

2,795

0.0035%

$1.96M

+1,607%

Stuart Essig

Director

—

2,236

0.0028%

$1.57M

—

Martin Alexander Smith

Executive Vice President

—

2,157

0.0027%

$1.51M

+1,702%

Asha COLLINS

Director

—

779

0.0010%

$546.61K

—

Joseph L Hooley

Director

—

373

0.0005%

$261.73K

—

Irene Chang Britt

Director

—

208

0.0003%

$145.95K

—

Karen Peacock

Director

—

102

0.0001%

$71.57K

+10,100%

Idexx Laboratories

What the insiders did Net selling

By person